ArticleJournal of cosmetic dermatology2024
A Well-Tolerated Hair Serum Containing New Natural Active Ingredients Reduced Hair Loss and Improved Quality of Life in Women With Chronic Telogen Effluvium: A 16-Week Controlled Study.
Article in Journal of cosmetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic telogen effluvium (CTE) is characterized by hair loss lasting for more than 6 months and severely impairs quality of life (QoL). There is no specific treatment.
aimsTo assess the dermatological tolerance and clinical efficacy of a hair serum containing three plant-derived active ingredients (a Silybum marianum extract, Manganese PCA, and a Lespedeza capitata extract) in women with CTE.
methodsIn this 16-week, open-label, two-arm, controlled, parallel-group study, 64 women aged 46 ± 10 years with CTE and a positive hair pull test were allocated equally to either a treated group (study serum and neutral shampoo) or a control group (neutral shampoo only).
resultsThe investigator rated dermatological tolerance of the serum as good at week (W)16. Compared to the control group, reductions in the amount of hair collected by the investigator during hair pull tests were greater in the treated group at W8 (p = 0.027) and W16 (p = 0.030), the amount of hair shed in 60 s (assessed by the subjects) was significantly lower in the treated group from W4, and more subjects in the treated group reported a decrease in hair loss over the study period (p ≤ 0.01; all time points). The treated subjects also perceived a significant improvement in hair volume, density, strength, and thickness, and reported being less depressed, less annoyed and less embarrassed by their hair loss.
conclusionsThe serum was well-tolerated and had a significant anti-hair loss effect in women with CTE. This effect positively impacted QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.